Hormone-refractory prostate cancer+1
RecruitingStudy of PF-06821497 and Enzalutamide for Men with Advanced Prostate Cancer Resistant to Hormone Therapy
Study of PF-06821497 and Enzalutamide for Men with Advanced Prostate Cancer Resistant to Hormone Therapy
- Disease:Hormone-refractory prostate cancerProstate cancer metastatic
- Substances:Enzalutamide5,8-Dichloro-2-[(4-Methoxy-6-Methyl-2-Oxo-1,2-Dihydropyridin-3-Yl)Methyl]-7-[(R)-Methoxy(Oxetan-3-Yl)Methyl]-3,4-Dihydroisoquinolin-1(2H)-One
Czechia- Participants:18–64 years · 65+ years
- Substances:Enzalutamide
- Sponsor:Pfizer Inc.












